Antacid therapy and idiopathic pulmonary fibrosis: Cause for heartburn?

The Lancet Respiratory Medicine

Volumn 4, Issue 5, 2016, Pages 340-341

  Nathan, Steven D ^a  

^a INOVA HEART AND VASCULAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; NINTEDANIB; PIRFENIDONE; PLACEBO; PROTON PUMP INHIBITOR;

DISEASE ASSOCIATION; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GASTROESOPHAGEAL REFLUX; HEARTBURN; HOSPITAL ADMISSION; HUMAN; INFECTION; LUNG INFECTION; MORTALITY; NOTE; PNEUMONIA; PRIORITY JOURNAL; LUNG FIBROSIS;

ANTACIDS; HEARTBURN; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PULMONARY FIBROSIS;

EID: 84961875654     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)00102-8     Document Type: Note

References (10)

1. Tobin RW, Pope CE, Pellegrini CA, et al. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998, 158:1804-1808.
2. Lee JS, Ryu JH, Elicker BM, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 184:1390-1394.
3. Lee JS, Collard HR, Anstrom KJ, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med 2013, 1:369-376.
4. Kreuter M, Wuyts W, Renzoni E, et al. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir Med 2016, published online March 31. http://dx.doi.org/10.1016/S2213-2600(16)00067-9.
5. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012, 366:1968-1977. The Idiopathic Pulmonary Fibrosis Clinical Research Network.
6. Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012, 186:88-95.
7. Lambert AA, Lam JO, Paik JJ, et al. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One 2015, 10:e0128004.
8. Moayyedi P, Leontiadis GI The risks of PPI therapy. Nature Rev Gastro Hepatol 2012, 9:132-139.
9. Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med 2015, 192:e3-e19.
10. Raghu R, Crestani B, Bailes Z, et al. Effect of anti-acid medication on reduction in FVC decline with nintedanib. Eur Respir J 2015, published online Sept 1. 10.1183/13993003.congress-2015.OA4502.